Oramed Pharmaceuticals Inc. (ORMP)
Healthcare · NCM
Price as at 1 Oct 2026, 00:53 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Oramed Pharmaceuticals Inc. trades at $4.67, which is 93% below the $9.02 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 30 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 1.5 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
ORMP dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.250 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
ORMP passes 6 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
4 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$884.1K · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$490.4K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$199.9K · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$105.2K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in ORMP
Trades in ORMP disclosed by members of Congress and executive-branch officials, latest first:
- Brad Knott · HouseSell · $15,001 - $50,000 · traded 10 Jan 2025 · disclosed 25 Feb 2025
- Andrew Garbarino · HouseSell · $1,001 - $15,000 · traded 14 Jan 2022 · disclosed 14 Jan 2022
- Andrew Garbarino · HouseSell · $1,001 - $15,000 · traded 1 Oct 2021 · disclosed 3 Nov 2021
- Andrew Garbarino · HouseBuy · $1,001 - $15,000 · traded 23 Apr 2021 · disclosed 24 May 2021
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
ORMP peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Oramed Pharmaceuticals Inc. (ORMP) undervalued?
Against our fair value estimate of $9.02, ORMP at $4.67 is 93% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own ORMP?
4 of the institutions we track reported a position in ORMP in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is ORMP's P/E ratio?
ORMP trades at 1.5 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Oramed Pharmaceuticals Inc. (ORMP) pay a dividend?
Yes. Oramed Pharmaceuticals Inc. yields 6.20% at the current share price. It has paid $0.250 per share over the trailing twelve months. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its ORMP data?
Fundamentals for ORMP come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:53 UTC and is delayed. Our data quality score for this company is 88/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ORMP, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.